Table 5.

Comparison between atypical ANCA-negative and atypical ANCA-positive patients with HT in relation to circulating cytokines.

	HT Patients Atypical ANCA-Negative (n = 26)	HT Patients Atypical ANCA-Positive (n = 26 *)	p Value
IL-2, pg/mL	0.0 (0.0–0.0)	0.0 (0.0–2.5)	0.819
IL-4, pg/mL	0.0 (0.0–2.2)	0.7 (0.0–1.5)	0.960
IL-6, pg/mL	1.3 (0.8–2.1)	1.6 (0.8–2.6)	0.595
IL-8, pg/mL	11.5 (7.6–22.6)	13.7 (6.5–45.2)	0.985
IL-10, pg/mL	0.0 (0.0–1.4)	0.0 (0.0–1.3)	0.921
VEGF, pg/mL	175.1 (107.5–290.4)	170.6 (113.0–224.6)	0.927
INFγ, pg/mL	0.0 (0.0–0.0)	0.0 (0.0–0.0)	0.667
TNFα, pg/mL	2.6 (2.1–3.8)	2.8 (2.5–3.4)	0.812
IL-1α, pg/mL	0.4 (0.3–0.5)	0.5 (0.4–0.7)	0.068
IL-1β, pg/mL	0.0 (0.0–1.8)	0.0 (0.0–1.4)	0.215
MCP1, pg/mL	332.8 (241.6–429.6)	303.0 (262.6–422.1)	0.855
EGF, pg/mL	111.6 (61.2–161.6)	104.2 (67.1–150.1)	0.935

* one patient with atypical ANCA was excluded from the main HT cohort due to insufficient aliquot sample.